Total PSA: A Tissue-Specific Signal From the Prostate
Prostate-specific antigen is a protein enzyme made almost exclusively by the prostate's glandular cells. It belongs to the kallikrein family of serine proteases (KLK3) and is normally secreted into seminal fluid. Most PSA remains within the ejaculate, but a small fraction passes through the prostate ducts and surrounding tissue into the bloodstream. In blood, PSA circulates partly bound to protease inhibitors (mainly alpha-1-antichymotrypsin) and partly unbound ("free"). A total PSA test measures the combined amount of these bound and free forms to capture the overall prostate-derived PSA present in circulation.
PSA's biological job is to liquefy semen by cutting gel-forming proteins (semenogelins), which frees sperm to move. Its production is driven by androgens (testosterone via the androgen receptor). When measured in blood, total PSA acts as a tissue-specific signal of the prostate: it reflects how active the gland is and how intact its epithelial barrier and ducts are. More PSA reaches the blood when prostate cells are stimulated, the gland enlarges, or the tissue is disrupted, so total PSA serves as a proxy for prostate tissue activity and permeability.
Why a Small Spillover Into Blood Tells a Big Story
Prostate Specific Antigen (PSA) is a protein made by prostate gland cells. A small amount normally leaks into blood, so the PSA test acts as a window into prostate biology—how active the gland is, whether it's inflamed or enlarged, and whether cells are behaving abnormally. Because prostate health affects urinary flow, sexual function, and, in advanced disease, bone and systemic health, PSA helps connect urologic, endocrine, and whole-body status.
Reading the Number and Its Trajectory
Typical reference ranges sit low for most adult men and rise modestly with age and prostate size. The healthiest values tend to be toward the lower end and, most importantly, stable over time.
Very low results usually reflect a small, quiet prostate, lower androgen-driven activity, or the expected effect after prostate removal or androgen-lowering therapy. They rarely cause symptoms and aren't harmful. In boys and in people without a prostate, levels are near zero.
Higher values mean more PSA is crossing into blood because the gland is larger, inflamed, or disrupted. Benign enlargement can lift PSA and often accompanies urinary frequency, weak stream, or nocturia. Prostatitis can spike PSA and may bring pelvic pain or fever. Recent ejaculation, instrumentation, or vigorous cycling can transiently raise it. Persistently high or rapidly rising values increase concern for prostate cancer, which is often silent early and may cause bone pain or weight loss when advanced.
Being in range suggests stable, age-appropriate prostate size, intact epithelial barriers, and minimal inflammatory activity. Within age-adjusted reference intervals, lower values are generally associated with lower risk, and the healthiest values often sit toward the lower end of those ranges.
Activities and Medications That Move PSA
PSA rises with age and prostate size. Recent ejaculation, cycling/pressure on the perineum, digital prostate manipulation, catheterization, cystoscopy, and biopsy can transiently increase results. 5-alpha-reductase inhibitors and antiandrogens lower PSA; testosterone can modestly raise it. Different assays vary. Total PSA includes free and protein-bound fractions; the free-to-total ratio can add context. After prostatectomy, any detectable PSA is clinically significant.
Total PSA Alongside Free PSA, Exam, and Imaging
Big picture: PSA integrates androgen signaling, prostate structure, and inflammation. Tracked over time alongside examination and imaging, it refines risk for significant prostate disease. Lower and stable suggests low risk; higher and rising signals greater likelihood of urinary morbidity and, in some men, clinically important cancer.
What Tracking PSA Over Time Tells You
Prostate Specific Antigen (PSA), Total measures the amount of a protease made by prostate epithelial cells that normally helps liquefy semen. A small spillover into blood is expected. Because PSA in blood rises when prostate tissue grows, becomes inflamed, or its barriers are disrupted, it serves as an index of prostate cell mass and integrity, linking to urinary and reproductive function and, when markedly abnormal, to cancer biology and systemic inflammation.
FAQs
A blood test that measures all circulating prostate-specific antigen, both bound and unbound, to reflect overall prostate activity.
To establish a baseline, track changes over time, support evaluation of prostate conditions, and monitor after treatment.
Often annually from midlife, or more frequently if risk factors (family history, ancestry, rising results) or prior treatment apply.
Age, BPH, prostatitis, urinary infection, ejaculation, cycling, prostate procedures, medications such as 5-alpha-reductase inhibitors, and prostate cancer.
Yes. Avoid ejaculation for 48 hours, pause vigorous cycling, and schedule testing before or several days after a digital rectal exam. Wait several weeks after infection or prostatitis.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- US Preventive Services Task Force. (2018). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA, 319(18), 1901-1913. https://doi.org/10.1001/jama.2018.3710
- Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N., Parson, R. E., Gasior, G. H., Loveland, K. G., & Southwick, P. C. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279(19), 1542-1547. https://doi.org/10.1001/jama.279.19.1542
- National Cancer Institute. (2022). Prostate-specific antigen (PSA) test. https://www.cancer.gov/types/prostate/psa-fact-sheet
- Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Páez, A., Määttänen, L., Bangma, C. H., Aus, G., Carlsson, S., Villers, A., Rebillard, X., ... Auvinen, A. (2012). Prostate-cancer mortality at 11 years of follow-up. New England Journal of Medicine, 366(11), 981-990. https://doi.org/10.1056/NEJMoa1113135
- Andriole, G. L., Crawford, E. D., Grubb, R. L., 3rd, Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., Weissfeld, J. L., Yokochi, L. A., O'Brien, B., Clapp, J. D., Rathmell, J. M., Riley, T. L., Hayes, R. B., Kramer, B. S., Izmirlian, G., ... Berg, C. D. (2009). Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine, 360(13), 1310-1319. https://doi.org/10.1056/NEJMoa0810696






































.avif)
